Skip to main content
Top
Published in: Pediatric Rheumatology 1/2020

Open Access 01-12-2020 | Juvenile Rheumatoid Arthritis | Research article

Longitudinal assessment of racial disparities in juvenile idiopathic arthritis disease activity in a treat-to-target intervention

Authors: Joyce C. Chang, Rui Xiao, Jon M. Burnham, Pamela F. Weiss

Published in: Pediatric Rheumatology | Issue 1/2020

Login to get access

Abstract

Background

We sought to evaluate racial disparities in disease outcomes among children with polyarticular juvenile idiopathic arthritis (JIA) during a treat-to-target (TTT) intervention with clinical decision support (CDS).

Methods

This was a retrospective analysis of a TTT-CDS strategy integrated into clinical practice for children with polyarticular JIA at a single center from 2016 to 2019. The primary outcome was the clinical Juvenile Arthritis Disease Activity Score (cJADAS-10). We used multivariable linear regression to assess racial differences in disease outcomes at the index visit (first visit after implementation). The effect of race on disease outcomes over time was estimated using linear mixed-effects models, stratified by incident or prevalent disease.

Results

We included 159 children with polyarticular JIA, of which 74, 13 and 13% were white, black, and Asian/other, respectively. cJADAS-10 improved significantly over time for all race categories, while the rates of improvement did not differ by race in incident (p = 0.53) or prevalent cases (p = 0.58). cJADAS-10 over time remained higher among black children compared to white children (β 2.5, p < 0.01 and β 1.2, p = 0.08 for incident and prevalent cases, respectively). Provider attestation to CDS use at ≥50% of encounters was associated with a 3.9 greater reduction in cJADAS-10 among black children compared to white children (p = 0.02).

Conclusion

Despite similar rates of improvement over time by race, disparities in JIA outcomes persisted throughout implementation of a TTT-CDS approach. More consistent CDS use may have a greater benefit among black children and needs to be explored further.
Literature
1.
go back to reference Wallace CA, Huang B, Bandeira M, Ravelli A, Giannini EH. Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum. 2005;52(11):3554–62.CrossRef Wallace CA, Huang B, Bandeira M, Ravelli A, Giannini EH. Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum. 2005;52(11):3554–62.CrossRef
2.
go back to reference Ringold S, Weiss PF, Colbert RA, DeWitt EM, Lee T, Onel K, et al. Childhood arthritis and rheumatology research Alliance consensus treatment plans for new-onset polyarticular juvenile idiopathic arthritis. Arthritis Care Res. 2014;66(7):1063–72.CrossRef Ringold S, Weiss PF, Colbert RA, DeWitt EM, Lee T, Onel K, et al. Childhood arthritis and rheumatology research Alliance consensus treatment plans for new-onset polyarticular juvenile idiopathic arthritis. Arthritis Care Res. 2014;66(7):1063–72.CrossRef
3.
go back to reference Ringold S, Beukelman T, Nigrovic PA, Kimura Y. CARRA registry site principal investigators, Birmingham J, et al. race, ethnicity, and disease outcomes in juvenile idiopathic arthritis: a cross-sectional analysis of the childhood arthritis and rheumatology research Alliance (CARRA) registry. J Rheumatol. 2013;40(6):936–42.CrossRef Ringold S, Beukelman T, Nigrovic PA, Kimura Y. CARRA registry site principal investigators, Birmingham J, et al. race, ethnicity, and disease outcomes in juvenile idiopathic arthritis: a cross-sectional analysis of the childhood arthritis and rheumatology research Alliance (CARRA) registry. J Rheumatol. 2013;40(6):936–42.CrossRef
4.
go back to reference Bruce B, Fries JF, Murtagh KN. Health status disparities in ethnic minority patients with rheumatoid arthritis: a cross-sectional study. J Rheumatol. 2007;34(7):1475–9.PubMed Bruce B, Fries JF, Murtagh KN. Health status disparities in ethnic minority patients with rheumatoid arthritis: a cross-sectional study. J Rheumatol. 2007;34(7):1475–9.PubMed
5.
go back to reference Kerr GS, Swearingen C, Mikuls TR, Yazici Y. Use of biologic therapy in racial minorities with rheumatoid arthritis from 2 US health care systems: JCR. J Clin Rheumatol. 2017;23(1):12–8.CrossRef Kerr GS, Swearingen C, Mikuls TR, Yazici Y. Use of biologic therapy in racial minorities with rheumatoid arthritis from 2 US health care systems: JCR. J Clin Rheumatol. 2017;23(1):12–8.CrossRef
6.
go back to reference Chu L-H, Portugal C, Kawatkar AA, Stohl W, Nichol MB. Racial/ethnic differences in the use of biologic disease-modifying antirheumatic drugs among California Medicaid rheumatoid arthritis patients. Arthritis Care Res. 2013;65(2):299–303.CrossRef Chu L-H, Portugal C, Kawatkar AA, Stohl W, Nichol MB. Racial/ethnic differences in the use of biologic disease-modifying antirheumatic drugs among California Medicaid rheumatoid arthritis patients. Arthritis Care Res. 2013;65(2):299–303.CrossRef
7.
go back to reference Schmajuk G, Trivedi AN, Solomon DH, Yelin E, Trupin L, Chakravarty EF, et al. Receipt of disease-modifying Antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans. JAMA. 2011;305(5):480.CrossRef Schmajuk G, Trivedi AN, Solomon DH, Yelin E, Trupin L, Chakravarty EF, et al. Receipt of disease-modifying Antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans. JAMA. 2011;305(5):480.CrossRef
8.
go back to reference Bridges SL, Causey ZL, Burgos PI, Huynh BQN, Hughes LB, Danila MI, et al. Radiographic severity of rheumatoid arthritis in African Americans: results from a multicenter observational study. Arthritis Care Res. 2010;62(5):624–31.CrossRef Bridges SL, Causey ZL, Burgos PI, Huynh BQN, Hughes LB, Danila MI, et al. Radiographic severity of rheumatoid arthritis in African Americans: results from a multicenter observational study. Arthritis Care Res. 2010;62(5):624–31.CrossRef
9.
go back to reference McBurney CA, Vina ER. Racial and ethnic disparities in rheumatoid arthritis. Curr Rheumatol Rep. 2012;14(5):463–71.CrossRef McBurney CA, Vina ER. Racial and ethnic disparities in rheumatoid arthritis. Curr Rheumatol Rep. 2012;14(5):463–71.CrossRef
10.
go back to reference Chin MH, Walters AE, Cook SC, Huang ES. Interventions to Reduce Racial and Ethnic Disparities in Health Care. Med Care Res Rev. 2007;64(5_suppl):7S–28S.CrossRef Chin MH, Walters AE, Cook SC, Huang ES. Interventions to Reduce Racial and Ethnic Disparities in Health Care. Med Care Res Rev. 2007;64(5_suppl):7S–28S.CrossRef
11.
go back to reference Fransen J, Moens HB, Speyer I, van Riel PLCM. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Ann Rheum Dis. 2005;64(9):1294–8.CrossRef Fransen J, Moens HB, Speyer I, van Riel PLCM. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Ann Rheum Dis. 2005;64(9):1294–8.CrossRef
12.
go back to reference Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet Lond Engl. 2004;364(9430):263–9.CrossRef Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet Lond Engl. 2004;364(9430):263–9.CrossRef
13.
go back to reference Klein A, Minden K, Hospach A, Foeldvari I, Weller-Heinemann F, Trauzeddel R, et al. Treat-to-target study for improved outcome in polyarticular juvenile idiopathic arthritis. Ann Rheum Dis. 2020. Klein A, Minden K, Hospach A, Foeldvari I, Weller-Heinemann F, Trauzeddel R, et al. Treat-to-target study for improved outcome in polyarticular juvenile idiopathic arthritis. Ann Rheum Dis. 2020.
14.
go back to reference Hissink Muller P, Brinkman DMC, Schonenberg-Meinema D, van den Bosch WB, Koopman-Keemink Y, Brederije ICJ, et al. Treat to target (drug-free) inactive disease in DMARD-naive juvenile idiopathic arthritis: 24-month clinical outcomes of a three-armed randomised trial. Ann Rheum Dis. 2019;78(1):51–9.CrossRef Hissink Muller P, Brinkman DMC, Schonenberg-Meinema D, van den Bosch WB, Koopman-Keemink Y, Brederije ICJ, et al. Treat to target (drug-free) inactive disease in DMARD-naive juvenile idiopathic arthritis: 24-month clinical outcomes of a three-armed randomised trial. Ann Rheum Dis. 2019;78(1):51–9.CrossRef
15.
go back to reference Ravelli A, Consolaro A, Horneff G, Laxer RM, Lovell DJ, Wulffraat NM, et al. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2018;77(6):819–28.PubMed Ravelli A, Consolaro A, Horneff G, Laxer RM, Lovell DJ, Wulffraat NM, et al. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2018;77(6):819–28.PubMed
16.
go back to reference Schoemaker CG, Swart JF, Wulffraat NM. Treating juvenile idiopathic arthritis to target: what is the optimal target definition to reach all goals? Pediatr Rheumatol Online J. 2020;18(1):34.CrossRef Schoemaker CG, Swart JF, Wulffraat NM. Treating juvenile idiopathic arthritis to target: what is the optimal target definition to reach all goals? Pediatr Rheumatol Online J. 2020;18(1):34.CrossRef
17.
go back to reference Buckley L, Ware E, Kreher G, Wiater L, Mehta J, Burnham JM. Outcome monitoring and clinical decision support in Polyarticular juvenile idiopathic arthritis. J Rheumatol. 2020;47(2):273–81.CrossRef Buckley L, Ware E, Kreher G, Wiater L, Mehta J, Burnham JM. Outcome monitoring and clinical decision support in Polyarticular juvenile idiopathic arthritis. J Rheumatol. 2020;47(2):273–81.CrossRef
18.
go back to reference Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3–15.CrossRef Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3–15.CrossRef
19.
go back to reference Mcerlane F, Beresford MW, Baildam EM, Chieng SEA, Davidson JE, Foster HE, et al. Validity of a three-variable juvenile arthritis disease activity score in children with new-onset juvenile idiopathic arthritis. Ann Rheum Dis. 2013;72(12):1983–8.CrossRef Mcerlane F, Beresford MW, Baildam EM, Chieng SEA, Davidson JE, Foster HE, et al. Validity of a three-variable juvenile arthritis disease activity score in children with new-onset juvenile idiopathic arthritis. Ann Rheum Dis. 2013;72(12):1983–8.CrossRef
20.
go back to reference DeWitt EM, Stucky BD, Thissen D, Irwin DE, Langer M, Varni JW, et al. Construction of the eight-item patient-reported outcomes measurement information system pediatric physical function scales: built using item response theory. J Clin Epidemiol. 2011;64(7):794–804.CrossRef DeWitt EM, Stucky BD, Thissen D, Irwin DE, Langer M, Varni JW, et al. Construction of the eight-item patient-reported outcomes measurement information system pediatric physical function scales: built using item response theory. J Clin Epidemiol. 2011;64(7):794–804.CrossRef
21.
go back to reference Brandon TG, Becker BD, Bevans KB, Weiss PF. Patient-reported outcomes measurement information system tools for collecting patient-reported outcomes in children with juvenile arthritis: validity of PROMIS tools for juvenile arthritis. Arthritis Care Res. 2017;69(3):393–402.CrossRef Brandon TG, Becker BD, Bevans KB, Weiss PF. Patient-reported outcomes measurement information system tools for collecting patient-reported outcomes in children with juvenile arthritis: validity of PROMIS tools for juvenile arthritis. Arthritis Care Res. 2017;69(3):393–402.CrossRef
22.
go back to reference Consolaro A, Negro G, Chiara Gallo M, Bracciolini G, Ferrari C, Schiappapietra B, et al. Defining criteria for disease activity states in nonsystemic juvenile idiopathic arthritis based on a three-variable juvenile arthritis disease activity score: cutoffs of the three-variable JADAS. Arthritis Care Res. 2014;66(11):1703–9.CrossRef Consolaro A, Negro G, Chiara Gallo M, Bracciolini G, Ferrari C, Schiappapietra B, et al. Defining criteria for disease activity states in nonsystemic juvenile idiopathic arthritis based on a three-variable juvenile arthritis disease activity score: cutoffs of the three-variable JADAS. Arthritis Care Res. 2014;66(11):1703–9.CrossRef
23.
go back to reference Greenberg JD, Spruill TM, Shan Y, Reed G, Kremer JM, Potter J, et al. Racial and ethnic disparities in disease activity in patients with rheumatoid arthritis. Am J Med. 2013;126(12):1089–98.CrossRef Greenberg JD, Spruill TM, Shan Y, Reed G, Kremer JM, Potter J, et al. Racial and ethnic disparities in disease activity in patients with rheumatoid arthritis. Am J Med. 2013;126(12):1089–98.CrossRef
24.
go back to reference Barton JL, Trupin L, Schillinger D, Gansky SA, Tonner C, Margaretten M, et al. Racial and ethnic disparities in disease activity and function among persons with rheumatoid arthritis from university-affiliated clinics. Arthritis Care Res. 2011;63(9):1238–46.CrossRef Barton JL, Trupin L, Schillinger D, Gansky SA, Tonner C, Margaretten M, et al. Racial and ethnic disparities in disease activity and function among persons with rheumatoid arthritis from university-affiliated clinics. Arthritis Care Res. 2011;63(9):1238–46.CrossRef
25.
go back to reference Minden K, Horneff G, Niewerth M, Seipelt E, Aringer M, Aries P, et al. Time of disease-modifying Antirheumatic drug start in juvenile idiopathic arthritis and the likelihood of a drug-free remission in young adulthood. Arthritis Care Res. 2019;71(4):471–81.CrossRef Minden K, Horneff G, Niewerth M, Seipelt E, Aringer M, Aries P, et al. Time of disease-modifying Antirheumatic drug start in juvenile idiopathic arthritis and the likelihood of a drug-free remission in young adulthood. Arthritis Care Res. 2019;71(4):471–81.CrossRef
26.
go back to reference Constantinescu F, Goucher S, Weinstein A, Fraenkel L. Racial disparities in treatment preferences for rheumatoid arthritis. Med Care. 2009;47(3):350–5.CrossRef Constantinescu F, Goucher S, Weinstein A, Fraenkel L. Racial disparities in treatment preferences for rheumatoid arthritis. Med Care. 2009;47(3):350–5.CrossRef
27.
go back to reference Constantinescu F, Goucher S, Weinstein A, Smith W, Fraenkel L. Understanding why rheumatoid arthritis patient treatment preferences differ by race. Arthritis Rheum. 2009;61(4):413–8.CrossRef Constantinescu F, Goucher S, Weinstein A, Smith W, Fraenkel L. Understanding why rheumatoid arthritis patient treatment preferences differ by race. Arthritis Rheum. 2009;61(4):413–8.CrossRef
28.
go back to reference Barton JL. The role of race in patient preferences for treatment in rheumatoid arthritis. Arthritis Rheum. 2009;61(4):411–2.CrossRef Barton JL. The role of race in patient preferences for treatment in rheumatoid arthritis. Arthritis Rheum. 2009;61(4):411–2.CrossRef
Metadata
Title
Longitudinal assessment of racial disparities in juvenile idiopathic arthritis disease activity in a treat-to-target intervention
Authors
Joyce C. Chang
Rui Xiao
Jon M. Burnham
Pamela F. Weiss
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Pediatric Rheumatology / Issue 1/2020
Electronic ISSN: 1546-0096
DOI
https://doi.org/10.1186/s12969-020-00485-y

Other articles of this Issue 1/2020

Pediatric Rheumatology 1/2020 Go to the issue